Recent research suggests that diabetes and weight loss medications, such as Mounjaro and Ozempic, may be beneficial for patients struggling with addiction. A study published on Thursday in the scientific journal Addiction indicates that individuals with opioid or alcohol use disorders who are prescribed Ozempic or similar medications experience a significant reduction in risks associated with substance use. Specifically, these patients show a 40% decrease in opioid overdose rates and a 50% reduction in instances of alcohol intoxication compared to those not taking these medications.
Dr. Céline Gounder, a medical contributor for CBS News and editor-at-large for public health at KFF Health News, highlighted the clinical significance of these findings.
The research utilized a comprehensive dataset, analyzing nearly a decade’s worth of data from patients across more than 100 health systems nationwide. Prior studies have also explored the potential of these medications to assist individuals in quitting smoking.
Dr. Gounder expressed optimism regarding the future use of these drugs for addiction treatment, emphasizing that further research is necessary. “We would need to see some randomized clinical trials over time to establish a true cause-and-effect relationship. This evidence is essential for the FDA to consider expanding the indications for these drugs, which would also influence insurance coverage,” she explained during an appearance on CBS Mornings.
However, she cautioned that these medications are not without risks. “These drugs affect the brain, and the long-term consequences of hormonal changes in this context are still unclear. Potential long-term risks for cancer remain uncertain,” Dr. Gounder noted. She also pointed out known risks, including pancreatitis, gallbladder issues, kidney complications, and some reports of suicidal thoughts, which raise valid concerns.
Related Topic:
Which Weight Loss Surgery Is Safer
